GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shanghai HeartCare Medical Technology Corp Ltd (HKSE:06609) » Definitions » EBIT

Shanghai HeartCare Medical Technology (HKSE:06609) EBIT : HK$-110.2 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Shanghai HeartCare Medical Technology EBIT?

Shanghai HeartCare Medical Technology's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was HK$-51.7 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-110.2 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Shanghai HeartCare Medical Technology's annualized ROC % for the quarter that ended in Dec. 2023 was -15.22%. Shanghai HeartCare Medical Technology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -29.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Shanghai HeartCare Medical Technology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 113.69%.


Shanghai HeartCare Medical Technology EBIT Historical Data

The historical data trend for Shanghai HeartCare Medical Technology's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai HeartCare Medical Technology EBIT Chart

Shanghai HeartCare Medical Technology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
-83.94 -254.37 -239.44 -222.34 -110.21

Shanghai HeartCare Medical Technology Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only -126.26 -77.34 -148.66 -58.53 -51.68

Competitive Comparison of Shanghai HeartCare Medical Technology's EBIT

For the Medical Devices subindustry, Shanghai HeartCare Medical Technology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai HeartCare Medical Technology's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Shanghai HeartCare Medical Technology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Shanghai HeartCare Medical Technology's EV-to-EBIT falls into.



Shanghai HeartCare Medical Technology EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-110.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai HeartCare Medical Technology  (HKSE:06609) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Shanghai HeartCare Medical Technology's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-92.582 * ( 1 - 17.83% )/( (516.83 + 482.62)/ 2 )
=-76.0746294/499.725
=-15.22 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1366.783 - 35.34 - ( 814.613 - max(0, 60.692 - 1130.644+814.613))
=516.83

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1313.896 - 42.509 - ( 788.767 - max(0, 65.388 - 1099.677+788.767))
=482.62

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Shanghai HeartCare Medical Technology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-103.366/( ( (168.696 + max(194.325, 0)) + (109.024 + max(240.911, 0)) )/ 2 )
=-103.366/( ( 363.021 + 349.935 )/ 2 )
=-103.366/356.478
=-29.00 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(64.757 + 174.717 + 8.787) - (35.34 + 0 + 18.596)
=194.325

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(84.126 + 159.734 + 57.067) - (42.509 + 0 + 17.507)
=240.911

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Shanghai HeartCare Medical Technology's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=-110.211/-96.943
=113.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai HeartCare Medical Technology EBIT Related Terms

Thank you for viewing the detailed overview of Shanghai HeartCare Medical Technology's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai HeartCare Medical Technology (HKSE:06609) Business Description

Traded in Other Exchanges
N/A
Address
No. 356, Zhengbo Road, Floor 1 and 3, Building 38, Pilot Free Trade Zone, Lingang New District, Shanghai, CHN
Shanghai HeartCare Medical Technology Corp Ltd is an innovative neuro-interventional medical device company. The company is committed to creating high-quality products for the prevention and treatment of stroke. Geographically, the Group's revenue is derived from Mainland China.
Executives
Ding Kui 2201 Interest of corporation controlled by you
Wisary Limited 2101 Beneficial owner
Wang Guohui
Shanghai Zandaqian Enterprise Management Consulting Center
Lyfe Capital Management Limited
Lyfe Capital Fund Iii (dragon), L.p.
Shanghai Weiyun Enterprise Management Consulting Partnership (lp)
Lyfe Columbia River Limited
Temasek Holdings (private) Limited
Elbrus Investments Pte. Ltd.
Fullerton Management Pte Ltd
Temasek Life Sciences Private Limited

Shanghai HeartCare Medical Technology (HKSE:06609) Headlines

No Headlines